Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-Target EGFR/c-Met Inhibitor Article

Fan, Dang, Dong, Haifeng, Li, Anqi et al. (2024). Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-Target EGFR/c-Met Inhibitor . CURRENT MEDICINAL CHEMISTRY, 10.2174/0109298673305941240605050450

cited authors

  • Fan, Dang; Dong, Haifeng; Li, Anqi; Zhang, Yuying; Wang, Shiyu; Tu, Yuanbiao; Wang, Linxiao

sustainable development goals

authors

publication date

  • June 24, 2024

published in

keywords

  • 1ST-LINE TREATMENT
  • ACQUIRED-RESISTANCE
  • AMPLIFICATION
  • Biochemistry & Molecular Biology
  • Chemistry, Medicinal
  • EGFR resistance
  • GEFITINIB
  • GROWTH-FACTOR RECEPTOR
  • LUNG-CANCER
  • Life Sciences & Biomedicine
  • MUTANT
  • OPEN-LABEL
  • PHASE-II TRIAL
  • Pharmacology & Pharmacy
  • ROC-based virtual screening
  • Science & Technology
  • TYROSINE KINASE INHIBITOR
  • biological activity evaluation
  • c-Met
  • drug discovery
  • dynamic simulation

publisher

  • BENTHAM SCIENCE PUBL LTD